MAO/DETECTION OF ANTIBODIES & PROTEINS--ISOLATION OF VIR

MAO/抗体检测

• 批准号: 2296502
• 负责人: Robert Walter Buckheit
• 金额: $ 9.2万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-30 至 1997-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2296502
• 关键词: MAO; DETECTION; ANTIBODIES; PROTEINS; ISOLATION

The HIV Preclinical Vaccine Development Master Agreement Program was initiated to enable the NIAID to provide resources to accelerate the development of promising vaccine approaches. Under this program, a series of vaccine studies have been initiated to evaluate candidate and prototype AIDS vaccines in nonhuman primates. These studies are designed to obtain more information about the efficacy and optimum presentation of candidate HIV vaccines that are in human Phase I clinical trials or proposed for such trials as well as prototype SIV vaccines of the same type as these HIV vaccines. other vaccine studies will evaluate prototype HIV or SIV vaccines that offer novel presentation systems, may be capable of eliciting broadly cross-reactive immune responses, or have shown promising preliminary results. NIAID has initiated collaborative arrangements with researchers who have agreed to provide HIV and SIV vaccines for immunization of nonhuman primates. In all of the vaccine studies, the nonhuman primates will be challenged after immunization to determine if protection from infection or from disease can be obtained. The contractors in Category E of the Master Agreement Program, including the contractor listed above, will provide the laboratory support for these various vaccine studies. The laboratory support work is divided into two parts. Part A pertains to animals immunized with HIV vaccines and challenged with SHIV, and Part B assays pertain to animals immunized with SIV vaccines and challenged with SIV. In all cases assays will be performed such as ELISA and Western Blots to assess the humoral immune responses of immunized macaques. Virus isolations such as co-culture and limiting dilution will be performed to determine if virus infection has occurred after virus challenge. The Category E contractors will maintain a test results database for each study, and will transfer data electronically to the AIDS Vaccine Evaluation Group Statistical and Coordinating Center. In addition, the Category E contractors will provide facilities and equipment to conduct biosafety level 2 or 3 laboratory work.

HIV临床前疫苗开发主协议计划 启动以使NIAID能够提供资源，以加速 开发有前途的疫苗方法。 在这个项目下，一系列 已经启动了疫苗研究，以评估候选疫苗和原型疫苗 非人类灵长类动物的艾滋病疫苗。 这些研究旨在获得 更多关于候选人的功效和最佳表现的信息 正在进行人体I期临床试验或拟用于此类试验的HIV疫苗 试验以及原型SIV疫苗相同类型的这些艾滋病毒 疫苗。 其他疫苗研究将评估原型HIV或SIV 提供新型呈现系统的疫苗可能能够引发 广泛的交叉反应性免疫反应，或已显示出有希望的 初步结果。 NIAID已启动与以下机构的合作安排： 研究人员已经同意提供艾滋病毒和SIV疫苗， 非人灵长类动物的免疫。 在所有的疫苗研究中， 非人灵长类动物将在免疫后被攻击以确定是否 可以获得免受感染或疾病的保护。 承包商 主协议计划E类，包括承包商 将为这些疫苗提供实验室支持 问题研究 实验室支持工作分为两个部分。 A部分 涉及用HIV疫苗免疫并用SHIV攻击的动物， 和部分B测定涉及用SIV疫苗免疫的动物， 挑战SIV 在所有情况下，将进行测定，如ELISA 和Western印迹来评估免疫的体液免疫应答。 猕猴 病毒分离，如共培养和有限稀释， 以确定病毒感染后是否发生病毒感染 挑战. E类承建商会保存测试结果 每个研究的数据库，并将以电子方式将数据传输到艾滋病 疫苗评估小组统计和协调中心。 此外，本发明还提供了一种方法， E类承建商会提供设施及设备， 生物安全2级或3级实验室工作。